Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $9.2 million.

  • Eton Pharmaceuticals' Operating Expenses rose 5912.31% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year increase of 5046.15%. This contributed to the annual value of $26.0 million for FY2024, which is 1687.41% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Operating Expenses of $9.2 million as of Q3 2025, which was up 5912.31% from $13.4 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Operating Expenses' 5-year high stood at $13.4 million during Q2 2025, with a 5-year trough of $4.4 million in Q4 2021.
  • For the 5-year period, Eton Pharmaceuticals' Operating Expenses averaged around $6.5 million, with its median value being $5.8 million (2024).
  • In the last 5 years, Eton Pharmaceuticals' Operating Expenses plummeted by 4431.18% in 2021 and then surged by 7790.6% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Operating Expenses (Quarter) stood at $4.4 million in 2021, then grew by 20.22% to $5.3 million in 2022, then grew by 6.13% to $5.6 million in 2023, then grew by 3.98% to $5.8 million in 2024, then skyrocketed by 57.65% to $9.2 million in 2025.
  • Its last three reported values are $9.2 million in Q3 2025, $13.4 million for Q2 2025, and $10.3 million during Q1 2025.